Growth and collaboration: Embracing new challenges facing China’s life sciences market


As part of the Chinese government’s healthcare reform efforts, the essential drug list (EDL) will create challenges and opportunities for China’s pharmaceutical companies, pharmaceutical distributors and hospitals, as well as trigger changes in how they operate and compete.